{"filings":[{"id":584316,"accession_number":"0001104659-26-065254","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-05-21T21:19:10+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond reports positive Phase 2 silevertinib results; mPFS 15.2 months in EGFR-NCM NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary mPFS 15.2 months (95% CI: 10.8, NE); median DOR not reached; 53% of patients remain on therapy.","CNS ORR 86%; no de novo brain metastases observed; 19 patients with brain metastases at baseline.","ORR 60%, DCR 91%; VAF reduction in all evaluable patients across 25 unique EGFR-NCMs including PACC.","No new safety signals; TRAEs > Grade 3 reduced to 28% after dose reduction; 150 mg QD selected for pivotal development.","Company plans to meet with FDA later this year to discuss pivotal development plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94805,"accession_number":"0001701541-26-000015","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q1 2026 net loss $9.0M; cash $118.3M; GBM trial dosed first patient","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.0M vs net income of $56.5M in Q1 2025 (prior year included license revenue).","Cash, cash equivalents, and investments $118.3M as of March 31, 2026; sufficient into 2H 2028.","R&D expenses $7.0M (down from $10.5M); G&A expenses $4.3M (down from $5.0M).","First patient dosed in Phase 2 trial of silevertinib + temozolomide for newly diagnosed EGFRvIII+ GBM.","Oral presentation of silevertinib Phase 2 frontline NSCLC data at ASCO 2026 on May 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107446,"accession_number":"0001701541-26-000008","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.","Cash, equivalents, investments $128.7M at Dec 31, 2025, funding operations into 2H 2028.","Silevertinib Phase 2 NSCLC update with preliminary DOR/PFS expected Q2 2026; randomized GBM trial to start Q2 2026.","R&D expenses $33.6M in FY2025, down 34% YoY due to restructuring and focus on silevertinib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123789,"accession_number":"0001104659-25-117975","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond reports 60% ORR for silevertinib in 1L NSCLC; plans Phase 2 GBM trial; cash into 2H 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60% ORR (26/43) in 1L NSCLC with 35 distinct non-classical EGFR mutations; 86% CNS ORR in patients with brain metastases.","No new safety signals; AEs managed with supportive care; 29/43 patients remain on therapy, longest >19 months.","Plans randomized Phase 2 trial of silevertinib+TMZ in ~150 ND GBM patients, initiated 1H 2026, preliminary data expected 2028.","Cash $135.5M as of Sep 30, 2025, now expected to fund operations into 2H 2028; partner assumed for NSCLC pivotal.","PFS and DOR data for NSCLC (recurrent and frontline) expected at medical meeting in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123788,"accession_number":"0001701541-25-000038","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q3 net loss $8.5M, cash $135.5M; silevertinib Phase 2 ORR data due Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $135.5M as of Sept 30, 2025; funds operations into Q4 2027.","Net loss $8.5M in Q3 2025 vs $15.6M in Q3 2024; R&D expenses fell to $7.4M from $12.9M.","ORR and preliminary duration of treatment data from silevertinib Phase 2 in 1L non-classical EGFRm NSCLC expected later this quarter.","PFS data from Phase 2 trial expected in H1 2026; company plans FDA feedback on registrational path.","Exploring partnership opportunities for silevertinib in NSCLC and glioblastoma."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140468,"accession_number":"0001701541-25-000029","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.","Net loss $10.6M in Q2 2025 vs $19.9M in Q2 2024; R&D expenses down to $9.3M.","Phase 2 trial of silevertinib in 1L non-classical EGFRm NSCLC fully enrolled (n=43); ORR & preliminary DOR data expected Q4 2025.","Exploring partnership opportunities for silevertinib in NSCLC and GBM; FDA meeting planned for 1H 2026 on registrational path."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158155,"accession_number":"0001104659-25-058893","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Black Diamond Therapeutics elects three Class II directors, ratifies PwC","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II directors elected: Behbahani (14.5M for, 20.0M withheld), Menzel (33.5M for, 0.96M withheld), Kulkarni (14.2M for, 20.3M withheld); 8.5M broker non-votes each.","Ratification of PwC as auditor for FY2025 passed: 42.48M for, 0.45M against, 59k abstain.","Annual meeting held June 12, 2025 with 42.99M shares present out of 56.68M outstanding, establishing quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158154,"accession_number":"0001701541-25-000021","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.","Cash, cash equivalents, and investments $152.4M as of March 31, 2025, up from $98.6M at Dec 31, 2024.","Guidance: cash sufficient to fund operations into Q4 2027.","Phase 2 data for BDTX-1535 in 1L NSCLC expected Q4 2025; FDA feedback on pivotal path planned.","Global licensing agreement with Servier for BDTX-4933 includes $70M upfront and up to $710M in milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176519,"accession_number":"0001104659-25-025338","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Black Diamond grants Servier worldwide license for BDTX-4933; $70M upfront, up to $710M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $70M; eligible for up to $710M in development/commercial milestones plus tiered royalties on global sales.","Servier will lead global development and commercialization of BDTX-4933 in RAF/RAS-mutant solid tumors, including NSCLC.","BDTX-4933 is a Phase 1 small molecule designed to target RAS mutations and RAF alterations with best-in-class potential.","Black Diamond continues to advance its MasterKey platform; deal provides non-dilutive capital to support pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176518,"accession_number":"0001701541-25-000014","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q4/FY2024 net loss $16M/$69.7M; cash $98.6M into Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and investments $98.6M at Dec 31, 2024, down from $131.4M at Dec 31, 2023.","Net loss for Q4 2024 was $16.0M, compared to $19.4M in Q4 2023; FY2024 net loss $69.7M vs $82.4M.","R&D expenses decreased to $12.3M in Q4 2024 from $15.3M in Q4 2023; FY2024 R&D $51.3M vs $59.4M.","Initial Phase 2 data for BDTX-1535 in newly diagnosed non-classical EGFRm NSCLC expected Q2 2025.","Cash runway expected into Q4 2026; management to seek FDA feedback on registrational path for BDTX-1535 in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193369,"accession_number":"0001701541-24-000040","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q3 net loss of $15.6M; BDTX-1535 Phase 2 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.6M in Q3 2024 vs $23.0M in Q3 2023; cash and investments $112.7M, sufficient into Q2 2026.","R&D expenses decreased to $12.9M from $16.2M YoY due to workforce efficiencies and reduced early discovery.","Announced restructuring in Oct 2024 to prioritize BDTX-1535 and extend cash runway; deprioritized BDTX-4933.","Initial Phase 2 data for BDTX-1535 in EGFRm NSCLC: 42% ORR in 19 patients with osimertinib resistance mutations; DOR ~8+ months in first 3 PRs.","Expects to disclose initial Phase 2 data in first-line and updated recurrent setting data plus FDA feedback in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193368,"accession_number":"0001104659-24-106676","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond restructures to focus on BDTX-1535; CFO and CPO depart; cash runway extended to Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.","Restructuring: reduction in force, deprioritize BDTX-4933 to seek partners, outsource CMC activities.","Cash runway extended into Q2 2026 due to restructuring cost savings.","BDTX-1535 Phase 2 data in frontline and recurrent EGFRm NSCLC expected Q1 2025 with potential registration path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209715,"accession_number":"0001104659-24-101874","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond reports initial Phase 2 data for BDTX-1535 showing 42% ORR in recurrent EGFRm NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["200 mg daily dose selected for pivotal development; favorable tolerability with no new safety signals.","Preliminary ORR of 42% (8/19) in patients with C797S or PACC osimertinib-resistance mutations; 14/19 remain on therapy.","Duration of response ~8+ months for first 3 partial responders; mean follow-up 4.7 months.","Regulatory feedback on registration path expected Q1 2025; initial first-line data expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209714,"accession_number":"0001701541-24-000028","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.","Net loss $19.9M in Q2 2024 vs $19.2M in Q2 2023; R&D expenses decreased to $12.6M from $13.2M.","Initial Phase 2 data for BDTX-1535 in 2L/3L EGFRm NSCLC on track for later Q3 2024; 1L data in Q1 2025.","Initial Phase 1 data for BDTX-4933 in KRASm NSCLC on track for Q4 2024; ESMO poster in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227856,"accession_number":"0001104659-24-069070","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Black Diamond Therapeutics shareholders approve officer liability limitation and elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved Amendment to limit officer liability as permitted by Delaware law.","Prakash Raman and Mark A. Velleca elected as Class I directors to serve until 2027.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2024.","Certificate of Amendment filed and effective June 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227855,"accession_number":"0001701541-24-000020","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.","Cash, equivalents, investments $115.2M as of Mar 31, 2024; runway into Q3 2025.","Phase 2 BDTX-1535 in 2L/3L EGFRm NSCLC initial data expected Q3 2024; 1L cohort enrollment ongoing, data Q1 2025.","ASCO June 1: Phase 1 BDTX-1535 GBM dose-escalation and window-of-opportunity trial results.","Board changes: Shannon Campbell and Prakash Raman appointed; Wendy Dixon and Alex Mayweg stepped down."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227854,"accession_number":"0001104659-24-046096","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Black Diamond Therapeutics appoints Shannon Campbell and Prakash Raman to board; Dixon and Mayweg resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy Dixon and Alex Mayweg resigned from board effective April 10, 2024; no disagreement cited.","Shannon Campbell (EVP/Chief Commercial Officer at Merus) appointed Class III director, will serve on Compensation Committee.","Prakash Raman (CEO of stealth biopharma) appointed Class I director, will serve on Audit and Nominating/Governance Committees.","New directors are independent under Nasdaq standards and will receive standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246651,"accession_number":"0001701541-24-000009","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q4 2023 net loss of $19.4M, ends year with $131.4M cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $19.4M vs $21.1M in Q4 2022; full year net loss $82.4M vs $91.2M.","Cash, cash equivalents, investments $131.4M at Dec 31, 2023; expected to fund operations into Q2 2025.","Dosed first patient in Phase 2 trial of BDTX-1535 in 1L non-classical EGFRm NSCLC; Phase 2 data expected Q3 2024.","GBM results for BDTX-1535 in Q2 2024, initial results for BDTX-4933 in KRASm NSCLC in Q4 2024.","R&D expenses decreased to $59.4M for FY2023 from $64.4M in FY2022, primarily due to reduced early discovery spend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}